Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection
Purpose: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease. Methods: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more seve...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2017-01-01
|
| Series: | Journal of Ophthalmic & Vision Research |
| Subjects: | |
| Online Access: | http://www.jovr.org/article.asp?issn=2008-322X;year=2017;volume=12;issue=1;spage=44;epage=52;aulast=Ghassemi |
| _version_ | 1797991447330291712 |
|---|---|
| author | Fariba Ghassemi Sohrab Afshari Mirak Hormoz Chams Siamak Sabour Mehdi Nilli Ahmadabadi Fereidoun Davatchi Farhad Shahram |
| author_facet | Fariba Ghassemi Sohrab Afshari Mirak Hormoz Chams Siamak Sabour Mehdi Nilli Ahmadabadi Fereidoun Davatchi Farhad Shahram |
| author_sort | Fariba Ghassemi |
| collection | DOAJ |
| description | Purpose: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease.
Methods: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist.
Results: Patients with a mean age of 30.6 ± 7.4 years received a mean number of 3.3 IVB injections during the 6 months. The mean preinjection vision was 0.6 ± 0.3 and 0.4 ± 0.4 LogMAR in the case and control groups, respectively, with no significant improvement at 6 months. Mean central foveal thickness was 375.3 ± 132.1 and 307.2 ± 84.5 μm in the case and control groups, respectively, and these changed to 401 ± 199.9 (P = 0.65) and 307.7 ± 82.8 μm (P = 0.73) at month 6, respectively. A statistically nonsignificant improvement in ME was observed during the first 3 months in the case group. However, it did not persist up to month 6 on an as-needed basis. IVB injections caused a disproportionate decrease in the thickness of macular subfields. A reduction in disc leakage was observed on FA (P = 0.058). Logistic regression analysis revealed no statistically significant predictive factor for an improvement in visual acuity (VA) and a reduction in foveal thickness.
Conclusion: During a 6-month period, IVB injections based on an as-needed protocol provided no statistically significant improvement in VA and ME. |
| first_indexed | 2024-04-11T08:52:23Z |
| format | Article |
| id | doaj.art-de88df4113614bb6b19cebbd624d1a42 |
| institution | Directory Open Access Journal |
| issn | 2008-322X |
| language | English |
| last_indexed | 2024-04-11T08:52:23Z |
| publishDate | 2017-01-01 |
| publisher | Knowledge E |
| record_format | Article |
| series | Journal of Ophthalmic & Vision Research |
| spelling | doaj.art-de88df4113614bb6b19cebbd624d1a422022-12-22T04:33:33ZengKnowledge EJournal of Ophthalmic & Vision Research2008-322X2017-01-01121445210.4103/jovr.jovr_254_15Characteristics of macular edema in behcet disease after intravitreal bevacizumab injectionFariba GhassemiSohrab Afshari MirakHormoz ChamsSiamak SabourMehdi Nilli AhmadabadiFereidoun DavatchiFarhad ShahramPurpose: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease. Methods: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist. Results: Patients with a mean age of 30.6 ± 7.4 years received a mean number of 3.3 IVB injections during the 6 months. The mean preinjection vision was 0.6 ± 0.3 and 0.4 ± 0.4 LogMAR in the case and control groups, respectively, with no significant improvement at 6 months. Mean central foveal thickness was 375.3 ± 132.1 and 307.2 ± 84.5 μm in the case and control groups, respectively, and these changed to 401 ± 199.9 (P = 0.65) and 307.7 ± 82.8 μm (P = 0.73) at month 6, respectively. A statistically nonsignificant improvement in ME was observed during the first 3 months in the case group. However, it did not persist up to month 6 on an as-needed basis. IVB injections caused a disproportionate decrease in the thickness of macular subfields. A reduction in disc leakage was observed on FA (P = 0.058). Logistic regression analysis revealed no statistically significant predictive factor for an improvement in visual acuity (VA) and a reduction in foveal thickness. Conclusion: During a 6-month period, IVB injections based on an as-needed protocol provided no statistically significant improvement in VA and ME.http://www.jovr.org/article.asp?issn=2008-322X;year=2017;volume=12;issue=1;spage=44;epage=52;aulast=GhassemiBehcet's Disease; Macular Edema; Intravitreal Bevacizumab; Uveitis |
| spellingShingle | Fariba Ghassemi Sohrab Afshari Mirak Hormoz Chams Siamak Sabour Mehdi Nilli Ahmadabadi Fereidoun Davatchi Farhad Shahram Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection Journal of Ophthalmic & Vision Research Behcet's Disease; Macular Edema; Intravitreal Bevacizumab; Uveitis |
| title | Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection |
| title_full | Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection |
| title_fullStr | Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection |
| title_full_unstemmed | Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection |
| title_short | Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection |
| title_sort | characteristics of macular edema in behcet disease after intravitreal bevacizumab injection |
| topic | Behcet's Disease; Macular Edema; Intravitreal Bevacizumab; Uveitis |
| url | http://www.jovr.org/article.asp?issn=2008-322X;year=2017;volume=12;issue=1;spage=44;epage=52;aulast=Ghassemi |
| work_keys_str_mv | AT faribaghassemi characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection AT sohrabafsharimirak characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection AT hormozchams characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection AT siamaksabour characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection AT mehdinilliahmadabadi characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection AT fereidoundavatchi characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection AT farhadshahram characteristicsofmacularedemainbehcetdiseaseafterintravitrealbevacizumabinjection |